NCT00528892已完成3 期
An Open-label, Randomized, 48-Week Study to Assess the Safety, Tolerability and Activity of Raltegravir When Replacing the Ritonavir-boosted PI Component of HAART in HIV-Infected Individuals With Viral Load Suppression on a Ritonavir-Boosted PI Containing Regimen.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 282
- 试验地点
- 1
- 主要终点
- The proportion of patients with treatment failure (i.e.: those with viral failure, developing new CDC-C events, switching assigned treatment for any cause, withdrawing consent, being lost to follow-up or dying)
研究概览
简要总结
The investigators hypothesis is that switching from a ritonavir-boosted PI to raltegravir may be associated with an at least non-inferior effectiveness, virological response and safety, and even a better tolerability profile with regard to lipid metabolism, insulin resistance, body fat distribution as compared with continuation of the baseline regimen in HIV-1 seropositive males or females at least 18 years of age and older on ritonavir-boosted PI plus at least 2 other drugs and plasma viral RNA below 50 copies/mL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is a male or female at least 18 years of age.
- •Women of childbearing potential must have a negative serum pregnancy test (HCG) within 10 days prior to randomization into the study.
- •Patients must use adequate birth control measures (barrier method.)
- •Patients must be HIV 1 seropositive using standard diagnostic criteria.
- •Patients must have two plasma viral RNA measurements below detection limits with the routine ultrasensitive method used at each participating site (at least <50 copies/mL) within 180 days prior to randomization into this study.
- •Patients must be on continuous therapy with HAART consisting of a ritonavir-boosted protease-inhibitor (PI) and at least two other antiretroviral agents for at least 6 months prior to randomization into this study, with no planned drug changes in the following 12 months. Boosted PIs can be indinavir, fosamprenavir, saquinavir, lopinavir, atazanavir, tipranavir or darunavir.
- •Patients must be considered clinically stable, in the opinion of the investigator, at the time of entry into the study; i.e., clinical status and all chronic medications should be unchanged for at least 14 days prior to randomization. Patients currently receiving treatment for an opportunistic infection may be allowed into the study as long as the above criteria are met. Prophylaxis for opportunistic infections consistent with standard treatment is permissible. .
- •The following laboratory values must be obtained within 2-4 weeks of randomization into the study:
- •Hemoglobin >8.0 g/dL.
- •Absolute neutrophil count > 750/mm3
- •Platelet count > 50,000/ mm3
- •Creatinine < 2.0 mg/dL.
- •Transaminases (ALAT, ASAT) <5xULN
排除标准
- •Pregnancy or breast feeding or women planning pregnancy during the study duration.
- •Patients on ART regimens not likely to be maintained during the whole study duration
- •Prior use of HIV integrase inhibitors.
- •Use of any investigational agents (other than ART on expanded access programme) within 90 days of randomization.
- •Alcohol or substance abuse which in the opinion of the investigator would interfere with patient compliance or safety.
- •Patients with an active opportunistic infection or malignancy. Patients with a chronic, stable opportunistic infection will be allowed to enter this study.
- •Any condition or history of any illness which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs to the patient.
- •Any patient with a diagnosis of visceral Kaposi's sarcoma. Patients with lymphedema secondary to cutaneous Kaposi's sarcoma, or with cutaneous or palatal Kaposi's sarcoma that has been treated with systemic immunosuppressive therapy must also be excluded.
- •Any patient with a diagnosis of acute hepatitis due to any cause. Patients with chronic hepatitis including chronic hepatitis B surface antigenemia chronic hepatitis C may enter the study as long as they have stable liver function tests and meet all inclusion criteria. Patients with acute exacerbations of chronic hepatitis are excluded.
研究组 & 干预措施
1
Experimental
Switch current boosted-PI to raltegravir 400 mg BID.
干预措施: Raltegravir (Drug)
2
Active Comparator
Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
干预措施: boosted PI (Drug)
结局指标
主要结局
The proportion of patients with treatment failure (i.e.: those with viral failure, developing new CDC-C events, switching assigned treatment for any cause, withdrawing consent, being lost to follow-up or dying)
时间窗: 48 weeks
次要结局
- The proportion of patients with viral failure while on assigned treatment (defined as two consecutive plasma HIV-RNA below detection limits)(48 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug UsersHepatitis CHIV InfectionsNCT01105611St. James's Hospital, Ireland40
已完成
不适用
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI RegimenVirus DiseasesHIVNCT00749580University of South Florida46
Unknown
4 期
Simplification From Protease Inhibitors to RaltegravirHIV InfectionsNCT00941083Hospital Carlos III, Madrid240
Unknown
不适用
Pilot Study of Raltegravir Lipodystrophy IISPHIV InfectionNCT01164605Southern California Institute for Research and Education30
已完成
2 期
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceHIV InfectionsNCT00046033National Institute of Allergy and Infectious Diseases (NIAID)118